Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19404 | 1.00 | EP300 (0.31) | EP300 | |
| SCHEMBL19405 | 1.00 | EP300 (0.31) | EP300 | |
| SCHEMBL15136270 | 0.85 | — | — | |
| SCHEMBL4296539 | 0.84 | EP300 (0.31) | EP300 | |
| SCHEMBL4296542 | 0.84 | EP300 (0.31) | EP300 | |
| SCHEMBL17164585 | 0.83 | — | — | |
| SCHEMBL20248 | 0.83 | NPSR1 (0.44) | — | |
| SCHEMBL19246 | 0.83 | NPSR1 (0.44) | — | |
| SCHEMBL452937 | 0.83 | NPSR1 (0.44) | — | |
| SCHEMBL18936288 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999715-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11858905-B1 | Cathepsin L inhibitors | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| CN-116589425-A | Cathepsin L inhibitors | 百放英库医药科技(北京)有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3837251-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| CN-113227070-A | ASK1 inhibitors | 比奥根MA公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3837251-A1 | ASK1 INHIBITING AGENTS | Biogen MA Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020036949-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8648200-B2 | Imidazole derivatives useful for the treatment of arthritis | ELI LILLY AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120302608-A1 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012161965-A1 | NOVEL IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF ARTHRITIS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | MAP3K1, MAP3K6, MAP3K10 | EP300 1736/4885 |
| US-20120302608-A1 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis | F12, IL1RN, ARG1 | EP300 376/4885 |
| US-11858905-B1 | Cathepsin L inhibitors | CTSV, CTSL, CTSB | EP300 1722/4885 |
| US-20110301181-A1 | halogen-substituted compounds | L3MBTL4, QSOX1, L3MBTL3 | EP300 3750/4885 |
| US-11999715-B2 | ASK1 inhibiting agents | MAP3K1, MAP3K6, MAP3K10 | EP300 1736/4885 |
| US-20150099766-A1 | Novel halogen-substituted compounds | L3MBTL4, PRDX4, PRDX1 | EP300 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.